{"id":6679,"date":"2024-11-21T15:01:45","date_gmt":"2024-11-21T14:01:45","guid":{"rendered":"https:\/\/beigen.vipdev.lndo.site\/us\/?post_type=publication&p=6679"},"modified":"2025-04-28T22:03:17","modified_gmt":"2025-04-28T20:03:17","slug":"matching-adjusted-indirect-comparisons-of-zanubrutinib-magnolia-bgb-3111-au-003-versus-ibrutinib-pcyc-1121-and-rituximab-chronos-3-in-relapsed-refractory-marginal-zone-lymphoma","status":"publish","type":"publication","link":"https:\/\/beonemedaffairs.com\/us\/publication\/matching-adjusted-indirect-comparisons-of-zanubrutinib-magnolia-bgb-3111-au-003-versus-ibrutinib-pcyc-1121-and-rituximab-chronos-3-in-relapsed-refractory-marginal-zone-lymphoma\/","title":{"rendered":"Matching-adjusted indirect comparisons of zanubrutinib (MAGNOLIA, BGB-3111-AU-003) versus ibrutinib (PCYC-1121) and rituximab (CHRONOS-3) in relapsed\/refractory marginal zone lymphoma"},"content":{"rendered":"","protected":false},"template":"","post-tag":[],"class_list":["post-6679","publication","type-publication","status-publish","hentry","disease_state-marginal-zone-lymphoma","molecule-zanubrutinib"],"acf":[],"_links":{"self":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication\/6679","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/publication"}],"about":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/types\/publication"}],"wp:attachment":[{"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/media?parent=6679"}],"wp:term":[{"taxonomy":"post-tag","embeddable":true,"href":"https:\/\/beonemedaffairs.com\/us\/wp-json\/wp\/v2\/post-tag?post=6679"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}